B

Broncus Holding Corp
HKEX:2216

Watchlist Manager
Broncus Holding Corp
HKEX:2216
Watchlist
Price: 0.49 HKD 6.52% Market Closed
Market Cap: 258.3m HKD
Have any thoughts about
Broncus Holding Corp?
Write Note

Broncus Holding Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Broncus Holding Corp
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
B
Broncus Holding Corp
HKEX:2216
Income from Continuing Operations
-$28.1m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Income from Continuing Operations
ÂĄ522.1m
CAGR 3-Years
71%
CAGR 5-Years
99%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Income from Continuing Operations
ÂĄ1.7B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
19%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Income from Continuing Operations
ÂĄ12.4B
CAGR 3-Years
16%
CAGR 5-Years
23%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Income from Continuing Operations
ÂĄ794.1m
CAGR 3-Years
-11%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Income from Continuing Operations
ÂĄ2B
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Broncus Holding Corp
Glance View

Market Cap
258.3m HKD
Industry
Health Care

Broncus Holding Corp. engages in provision of interventional diagnosis and therapeutics solutions. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.

Intrinsic Value
0.63 HKD
Undervaluation 22%
Intrinsic Value
Price
B

See Also

What is Broncus Holding Corp's Income from Continuing Operations?
Income from Continuing Operations
-28.1m USD

Based on the financial report for Dec 31, 2023, Broncus Holding Corp's Income from Continuing Operations amounts to -28.1m USD.

What is Broncus Holding Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
17%

Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Broncus Holding Corp have been 17% over the past three years .

Back to Top